Table 2.
Immunohistochemistry of HBME‐1, CK19 and GAL‐3 in thyroid tumors
| Groups | n (Frequency, %) | ||
|---|---|---|---|
| HBME‐1 | CK19 | GAL‐3 | |
| WDT‐UMP (WDT‐UB) (n = 30) | 12 (40.0) | 10 (33.3) | 11 (36.7) |
| PTC (n = 48) | |||
| EC‐PTC (n = 10) | 8 (80.0) | 8 (80.0) | 9 (90.0) |
| C‐PTC (n = 27) | 19 (70.4) | 19 (70.4) | 18 (66.7) |
| EFV‐PTC (n = 2) | 2 (100.0) | 1 (50.0) | 1 (50.0) |
| IFV‐PTC (n = 9) | 8 (88.9) | 7 (77.8) | 8 (88.9) |
| FTA (n = 29) | 6 (20.7) | 9 (31.0) | 7 (24.1) |
| FTC (n = 8) | 4 (50.0) | 3 (37.5) | 3 (37.5) |
| HTA (n = 5) | 0 (0.0) | 0 (0.0) | 1 (20%) |
CK19, cytokeratin 19; GAL‐3, galectin‐3.